Melanocortin-receptor pharmacology of PT-141
PT-141, also known as bremelanotide, is a cyclic peptide studied through melanocortin-receptor binding, signaling, and structure–activity research.
Overview
PT-141 is a cyclic melanocortin peptide derived from the Melanotan-II scaffold. Its laboratory identity is best understood through the melanocortin receptor family, a group of G-protein-coupled receptors whose ligand recognition depends strongly on peptide sequence and conformation.
Published research has compared the binding and functional activity of melanocortin peptides across receptor subtypes, using radioligand, cyclic-AMP, calcium, and structure–activity assays. This work shows why receptor subtype, cell background, and endpoint selection matter: a peptide can display different apparent potency or signaling behavior across assay systems.
The defensible VIVO framing is receptor pharmacology—not a consumer outcome. PT-141 can support controlled research into melanocortin ligand recognition and downstream signaling. The sources below do not establish safety, efficacy, dosing, administration, or an expected outcome for a VIVO product.
References
Peer-reviewed sources for the research summarised above. Vivo summarises published, third-party science and does not conduct or sponsor this research.
- Bednarek MA, MacNeil T, Kalyani RN, et al. (2001). Analogs of MT-II and melanocortin receptor selectivity: structure–activity relationships. Peptides; 22(11):1889–1896. View source ↗
- Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ (2007). Melanocortins and bremelanotide: receptor-focused research review. Current Topics in Medicinal Chemistry; 7(11):1137–1144. View source ↗
- Ericson MD, Lensing CJ, Fleming KA, Schlasner KN, Doering SR, Haskell-Luevano C (2017). Bench-top to clinical therapies: melanocortin ligands and receptor pharmacology. Biochimica et Biophysica Acta; 1863(10):2414–2435. View source ↗